{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:27:28Z","timestamp":1781893648338,"version":"3.54.5"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-025-01714-w","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:39:55Z","timestamp":1739903995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Roles and therapeutic potential of the SLC family in prostate cancer\u2014literature review"],"prefix":"10.1186","volume":"25","author":[{"given":"Yuanzhi","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingcheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"issue":"1","key":"1714_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. https:\/\/doi.org\/10.1038\/s41572-020-00243-0.","journal-title":"Nat Rev Dis Primers"},{"key":"1714_CR2","doi-asserted-by":"publisher","first-page":"1355551","DOI":"10.3389\/fonc.2024.1355551","volume":"14","author":"B Lu","year":"2024","unstructured":"Lu B, Liu Y, Yao Y, et al. Advances in sequencing and omics studies in prostate cancer: unveiling molecular pathogenesis and clinical applications. Front Oncol. 2024;14:1355551. https:\/\/doi.org\/10.3389\/fonc.2024.1355551.","journal-title":"Front Oncol"},{"key":"1714_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.urology.2019.03.029","volume":"130","author":"PK Modi","year":"2019","unstructured":"Modi PK, Herrel LA, Kaufman SR, et al. Urologist practice structure and spending for prostate cancer care. Urology. 2019;130:65\u201371. https:\/\/doi.org\/10.1016\/j.urology.2019.03.029.","journal-title":"Urology"},{"issue":"9","key":"1714_CR4","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1001\/jamaoncol.2020.2485","volume":"6","author":"K Nagpal","year":"2020","unstructured":"Nagpal K, Foote D, Tan F, et al. Development and validation of a deep learning algorithm for gleason grading of prostate cancer from biopsy specimens. JAMA Oncol. 2020;6(9):1372\u201380. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2485.","journal-title":"JAMA Oncol"},{"key":"1714_CR5","doi-asserted-by":"publisher","unstructured":"Wasim S, Lee S Y, Kim J. Complexities of prostate cancer. Int J Mol Sci 2022;23(22). https:\/\/doi.org\/10.3390\/ijms232214257.","DOI":"10.3390\/ijms232214257"},{"issue":"7","key":"1714_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000513258","volume":"99","author":"V Achard","year":"2021","unstructured":"Achard V, Panje CM, Engeler D, et al. Localized and locally advanced prostate cancer: treatment options. Oncology. 2021;99(7):413\u201321. https:\/\/doi.org\/10.1159\/000513258.","journal-title":"Oncology"},{"issue":"2","key":"1714_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4103\/0970-1591.52907","volume":"25","author":"A Bagrodia","year":"2009","unstructured":"Bagrodia A, Diblasio CJ, Wake RW, et al. Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues. Indian J Urol. 2009;25(2):169\u201376. https:\/\/doi.org\/10.4103\/0970-1591.52907.","journal-title":"Indian J Urol"},{"issue":"5","key":"1714_CR8","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044\u201360. https:\/\/doi.org\/10.3390\/curroncol29050247.","journal-title":"Curr Oncol"},{"key":"1714_CR9","doi-asserted-by":"publisher","first-page":"101952","DOI":"10.1016\/j.molmet.2024.101952","volume":"84","author":"K Hushmandi","year":"2024","unstructured":"Hushmandi K, Einollahi B, Saadat SH, et al. Amino acid transporters within the solute carrier superfamily: Underappreciated proteins and novel opportunities for cancer therapy. Molecular metabolism. 2024;84:101952. https:\/\/doi.org\/10.1016\/j.molmet.2024.101952.","journal-title":"Molecular metabolism"},{"key":"1714_CR10","doi-asserted-by":"publisher","unstructured":"Cordova RA, Misra J, Amin PH et al. GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis. Elife 2022;11. https:\/\/doi.org\/10.7554\/eLife.81083.","DOI":"10.7554\/eLife.81083"},{"issue":"1","key":"1714_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.apsb.2019.12.006","volume":"10","author":"W Song","year":"2020","unstructured":"Song W, Li D, Tao L, et al. Solute carrier transporters: the metabolic gatekeepers of immune cells. Acta Pharm Sin B. 2020;10(1):61\u201378. https:\/\/doi.org\/10.1016\/j.apsb.2019.12.006.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"1714_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pharmthera.2008.09.005","volume":"121","author":"V Ganapathy","year":"2009","unstructured":"Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009;121(1):29\u201340. https:\/\/doi.org\/10.1016\/j.pharmthera.2008.09.005.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"1714_CR13","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1111\/febs.15531","volume":"288","author":"MD Pizzagalli","year":"2021","unstructured":"Pizzagalli MD, Bensimon A, Superti-Furga G. A guide to plasma membrane solute carrier proteins. FEBS J. 2021;288(9):2784\u2013835. https:\/\/doi.org\/10.1111\/febs.15531.","journal-title":"FEBS J"},{"issue":"1","key":"1714_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu F, Yang J, Liu J, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218. https:\/\/doi.org\/10.1038\/s41392-021-00641-0.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1714_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-023-01453-1","volume":"16","author":"L Yang","year":"2023","unstructured":"Yang L, Chu Z, Liu M, et al. Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy. J Hematol Oncol. 2023;16(1):59. https:\/\/doi.org\/10.1186\/s13045-023-01453-1.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1714_CR16","doi-asserted-by":"publisher","first-page":"E592","DOI":"10.1152\/ajpendo.90645.2008","volume":"296","author":"J Avruch","year":"2009","unstructured":"Avruch J, Long X, Ortiz-Vega S, et al. Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab. 2009;296(4):E592-602. https:\/\/doi.org\/10.1152\/ajpendo.90645.2008.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1714_CR17","doi-asserted-by":"publisher","unstructured":"Pandrangi SL, Chittineedi P, Manthari RK et al. Impact of oxytosis on the cross-talk of mTORC with mitochondrial proteins in drug-resistant cancer stem cells. J Cell Physiol 2024: e31421. https:\/\/doi.org\/10.1002\/jcp.31421.","DOI":"10.1002\/jcp.31421"},{"key":"1714_CR18","doi-asserted-by":"publisher","first-page":"650355","DOI":"10.3389\/fonc.2021.650355","volume":"11","author":"X Peng","year":"2021","unstructured":"Peng X, Chen R, Cai S, et al. SLC1A4: a powerful prognostic marker and promising therapeutic target for HCC. Front Oncol. 2021;11:650355. https:\/\/doi.org\/10.3389\/fonc.2021.650355.","journal-title":"Front Oncol"},{"issue":"7835","key":"1714_CR19","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41586-020-2857-9","volume":"587","author":"M Shang","year":"2020","unstructured":"Shang M, Cappellesso F, Amorim R, et al. Macrophage-derived glutamine boosts satellite cells and muscle regeneration. Nature. 2020;587(7835):626\u201331. https:\/\/doi.org\/10.1038\/s41586-020-2857-9.","journal-title":"Nature"},{"issue":"9","key":"1714_CR20","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77(9):1745\u201370. https:\/\/doi.org\/10.1007\/s00018-019-03351-7.","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"1714_CR21","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1124\/dmd.113.051193","volume":"41","author":"EL Reyner","year":"2013","unstructured":"Reyner EL, Sevidal S, West MA, et al. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions. Drug Metab Dispos. 2013;41(8):1575\u201383. https:\/\/doi.org\/10.1124\/dmd.113.051193.","journal-title":"Drug Metab Dispos"},{"issue":"15","key":"1714_CR22","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.22.02221","volume":"41","author":"R Ferrarotto","year":"2023","unstructured":"Ferrarotto R, Sousa LG, Feng L, et al. Phase II Clinical trial of axitinib and avelumab in patients with recurrent\/metastatic adenoid cystic carcinoma. J Clin Oncol. 2023;41(15):2843\u201351. https:\/\/doi.org\/10.1200\/JCO.22.02221.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1714_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11523-009-0126-9","volume":"4","author":"RJ Kelly","year":"2009","unstructured":"Kelly RJ, Rixe O. Axitinib\u2013a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol. 2009;4(4):297\u2013305. https:\/\/doi.org\/10.1007\/s11523-009-0126-9.","journal-title":"Target Oncol"},{"issue":"15","key":"1714_CR24","doi-asserted-by":"publisher","first-page":"10558","DOI":"10.1021\/acs.jmedchem.3c00721","volume":"66","author":"AE Elsawi","year":"2023","unstructured":"Elsawi AE, Elbadawi MM, Nocentini A, et al. 1,5-Diaryl-1,2,4-triazole Ureas as New SLC-0111 analogues endowed with dual carbonic anhydrase and VEGFR-2 inhibitory activities. J Med Chem. 2023;66(15):10558\u201378. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00721.","journal-title":"J Med Chem"},{"issue":"3","key":"1714_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10456-024-09913-z","volume":"27","author":"F Yang","year":"2024","unstructured":"Yang F, Lee G, Fan Y. Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism. Angiogenesis. 2024;27(3):333\u201349. https:\/\/doi.org\/10.1007\/s10456-024-09913-z.","journal-title":"Angiogenesis"},{"key":"1714_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107358","volume":"147","author":"T Li","year":"2024","unstructured":"Li T, Wang J, Feng L, et al. Discovery of novel thiophene-3-carboxamide derivatives as potential VEGFR-2 inhibitors with anti-angiogenic properties. Bioorg Chem. 2024;147: 107358. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107358.","journal-title":"Bioorg Chem"},{"issue":"25","key":"1714_CR27","doi-asserted-by":"publisher","first-page":"11775","DOI":"10.7150\/thno.51655","volume":"10","author":"TC Chan","year":"2020","unstructured":"Chan TC, Wu WJ, Li WM, et al. SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma. Theranostics. 2020;10(25):11775\u201393. https:\/\/doi.org\/10.7150\/thno.51655.","journal-title":"Theranostics"},{"issue":"1","key":"1714_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13046-024-03114-8","volume":"43","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Yang Y, Qi X, et al. SLC14A1 and TGF-beta signaling: a feedback loop driving EMT and colorectal cancer metachronous liver metastasis. J Exp Clin Cancer Res. 2024;43(1):208. https:\/\/doi.org\/10.1186\/s13046-024-03114-8.","journal-title":"J Exp Clin Cancer Res"},{"issue":"39","key":"1714_CR29","doi-asserted-by":"publisher","first-page":"eadg8229","DOI":"10.1126\/sciadv.adg82295","volume":"9","author":"G Chi","year":"2023","unstructured":"Chi G, Dietz L, Tang H, et al. Structural characterization of human urea transporters UT-A and UT-B and their inhibition. Sci Adv. 2023;9(39):eadg8229. https:\/\/doi.org\/10.1126\/sciadv.adg82295.","journal-title":"Sci Adv"},{"issue":"11\u201312","key":"1714_CR30","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00424-019-02323-x","volume":"471","author":"L Yu","year":"2019","unstructured":"Yu L, Liu T, Fu S, et al. Physiological functions of urea transporter B. Pflugers Arch. 2019;471(11\u201312):1359\u201368. https:\/\/doi.org\/10.1007\/s00424-019-02323-x.","journal-title":"Pflugers Arch"},{"issue":"7","key":"1714_CR31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2967\/jnumed.124.267416","volume":"65","author":"N Pandit-Taskar","year":"2024","unstructured":"Pandit-Taskar N, O\u2019Donoghue JA, Chetty D, et al. A phase 0 study to assess the biodistribution and pharmacokinetics of a radiolabeled antibody targeting human Kallikrein 2 in participants with metastatic castration-resistant prostate cancer. J Nucl Med. 2024;65(7):1051\u20136. https:\/\/doi.org\/10.2967\/jnumed.124.267416.","journal-title":"J Nucl Med"},{"key":"1714_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/112_2013_17","volume":"166","author":"CA Goodman","year":"2014","unstructured":"Goodman CA. The role of mTORC1 in regulating protein synthesis and skeletal muscle mass in response to various mechanical stimuli. Rev Physiol Biochem Pharmacol. 2014;166:43\u201395. https:\/\/doi.org\/10.1007\/112_2013_17.","journal-title":"Rev Physiol Biochem Pharmacol"},{"issue":"3","key":"1714_CR33","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3892\/mmr.2012.956","volume":"6","author":"MH Vaarala","year":"2012","unstructured":"Vaarala MH, Hirvikoski P, Kauppila S, et al. Identification of androgen-regulated genes in human prostate. Mol Med Rep. 2012;6(3):466\u201372. https:\/\/doi.org\/10.3892\/mmr.2012.956.","journal-title":"Mol Med Rep"},{"issue":"1","key":"1714_CR34","doi-asserted-by":"publisher","first-page":"17064","DOI":"10.1038\/s41598-022-20775-7","volume":"12","author":"B Ye","year":"2022","unstructured":"Ye B, Ding K, Li K, et al. Study on the role of SLC14A1 gene in biochemical recurrence of prostate cancer. Sci Rep. 2022;12(1):17064. https:\/\/doi.org\/10.1038\/s41598-022-20775-7.","journal-title":"Sci Rep"},{"issue":"1","key":"1714_CR35","doi-asserted-by":"publisher","first-page":"14914","DOI":"10.1038\/s41598-024-66020-1","volume":"14","author":"J Ma","year":"2024","unstructured":"Ma J, Xue K, Jiang Y, et al. Down-regulation of SLC14A1 in prostate cancer activates CDK1\/CCNB1 and mTOR pathways and promotes tumor progression. Sci Rep. 2024;14(1):14914. https:\/\/doi.org\/10.1038\/s41598-024-66020-1.","journal-title":"Sci Rep"},{"issue":"5","key":"1714_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12032-024-02330-8","volume":"41","author":"A Elmetwalli","year":"2024","unstructured":"Elmetwalli A, Abdel-Monem MO, El-Far AH, et al. Probiotic-derived silver nanoparticles target mTOR\/MMP-9\/BCL-2\/dependent AMPK activation for hepatic cancer treatment. Med Oncol. 2024;41(5):106. https:\/\/doi.org\/10.1007\/s12032-024-02330-8.","journal-title":"Med Oncol"},{"issue":"5","key":"1714_CR37","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.3892\/mmr.2018.8653","volume":"17","author":"Y Zeng","year":"2018","unstructured":"Zeng Y, Yang Y. Piperine depresses the migration progression via downregulating the Akt\/mTOR\/MMP-9 signaling pathway in DU145 cells. Mol Med Rep. 2018;17(5):6363\u201370. https:\/\/doi.org\/10.3892\/mmr.2018.8653.","journal-title":"Mol Med Rep"},{"issue":"8","key":"1714_CR38","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1158\/1541-7786.Mcr-16-0480","volume":"15","author":"MA White","year":"2017","unstructured":"White MA, Lin C, Rajapakshe K, et al. Glutamine transporters are targets of multiple oncogenic signaling pathways in prostate cancer. Mol Cancer Res: MCR. 2017;15(8):1017\u201328. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-16-0480.","journal-title":"Mol Cancer Res: MCR"},{"issue":"4","key":"1714_CR39","first-page":"1563","volume":"61","author":"J Xu","year":"2001","unstructured":"Xu J, Kalos M, Stolk JA, et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res. 2001;61(4):1563\u20138.","journal-title":"Cancer Res"},{"issue":"1","key":"1714_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13000-023-01434-5","volume":"19","author":"F Viehweger","year":"2024","unstructured":"Viehweger F, Bocker C, Weidemann S, et al. Prostein expression in human tumors: a tissue microarray study on 19,202 tumors from 152 different tumor entities. Diagn Pathol. 2024;19(1):12. https:\/\/doi.org\/10.1186\/s13000-023-01434-5.","journal-title":"Diagn Pathol"},{"issue":"4","key":"1714_CR41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/ijc.27733","volume":"132","author":"S Perner","year":"2013","unstructured":"Perner S, Rupp NJ, Braun M, et al. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course. Int J Cancer. 2013;132(4):807\u201312. https:\/\/doi.org\/10.1002\/ijc.27733.","journal-title":"Int J Cancer"},{"issue":"9","key":"1714_CR42","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/pros.23176","volume":"76","author":"S Hern\u00e1ndez","year":"2016","unstructured":"Hern\u00e1ndez S, Font-Tello A, Juanpere N, et al. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset. Prostate. 2016;76(9):854\u201365. https:\/\/doi.org\/10.1002\/pros.23176.","journal-title":"Prostate"},{"issue":"4","key":"1714_CR43","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/modpathol.2009.193","volume":"23","author":"R Esgueva","year":"2010","unstructured":"Esgueva R, Perner S, LaFargue CJ, et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Modern Pathol. 2010;23(4):539\u201346. https:\/\/doi.org\/10.1038\/modpathol.2009.193.","journal-title":"Modern Pathol"},{"key":"1714_CR44","doi-asserted-by":"publisher","unstructured":"Kim J, Hwang KW, Lee HJ et al. Systematic analysis of cellular signaling pathways and therapeutic targets for SLC45A3:ERG Fusion-positive prostate cancer. J Person Med 2022;12(11). https:\/\/doi.org\/10.3390\/jpm12111818.","DOI":"10.3390\/jpm12111818"},{"key":"1714_CR45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","volume":"698","author":"S Noorolyai","year":"2019","unstructured":"Noorolyai S, Shajari N, Baghbani E, et al. The relation between PI3K\/AKT signalling pathway and cancer. Gene. 2019;698:120\u20138. https:\/\/doi.org\/10.1016\/j.gene.2019.02.076.","journal-title":"Gene"},{"issue":"5","key":"1714_CR46","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.37349\/etat.2024.00266","volume":"5","author":"N Thakur","year":"2024","unstructured":"Thakur N, Singh P, Bagri A, et al. Therapy resistance in prostate cancer: mechanism, signaling and reversal strategies. Explor Target Anti-tumor Ther. 2024;5(5):1110\u201334. https:\/\/doi.org\/10.37349\/etat.2024.00266.","journal-title":"Explor Target Anti-tumor Ther"},{"issue":"7","key":"1714_CR47","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2159-8290.CD-12-0042","volume":"2","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Gong M, Yuan H, et al. Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation. Cancer Discov. 2012;2(7):598\u2013607. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0042.","journal-title":"Cancer Discov"},{"issue":"7","key":"1714_CR48","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/0008-5472.Can-08-4926","volume":"69","author":"DS Rickman","year":"2009","unstructured":"Rickman DS, Pflueger D, Moss B, et al. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Can Res. 2009;69(7):2734\u20138. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-4926.","journal-title":"Can Res"},{"issue":"36","key":"1714_CR49","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1038\/onc.2008.125","volume":"27","author":"H Makkonen","year":"2008","unstructured":"Makkonen H, J\u00e4\u00e4skel\u00e4inen T, Pitk\u00e4nen-Arsiola T, et al. Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells. Oncogene. 2008;27(36):4865\u201376. https:\/\/doi.org\/10.1038\/onc.2008.125.","journal-title":"Oncogene"},{"issue":"10","key":"1714_CR50","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP, Coleman IM, Brown LG, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019;129(10):4492\u2013505. https:\/\/doi.org\/10.1172\/JCI128212.","journal-title":"J Clin Invest"},{"issue":"4","key":"1714_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/apm.12504","volume":"124","author":"AH Seipel","year":"2016","unstructured":"Seipel AH, Samaratunga H, Delahunt B, et al. Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study. APMIS. 2016;124(4):263\u201370. https:\/\/doi.org\/10.1111\/apm.12504.","journal-title":"APMIS"},{"issue":"1","key":"1714_CR52","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/modpathol.2014.77","volume":"28","author":"A Queisser","year":"2015","unstructured":"Queisser A, Hagedorn SA, Braun M, et al. Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer. Mod Pathol. 2015;28(1):138\u201345. https:\/\/doi.org\/10.1038\/modpathol.2014.77.","journal-title":"Mod Pathol"},{"issue":"9","key":"1714_CR53","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1097\/PAS.0b013e3180536678","volume":"31","author":"T Sheridan","year":"2007","unstructured":"Sheridan T, Herawi M, Epstein JI, et al. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol. 2007;31(9):1351\u20135. https:\/\/doi.org\/10.1097\/PAS.0b013e3180536678.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1714_CR54","doi-asserted-by":"publisher","first-page":"16","DOI":"10.31083\/j.fbl2901016","volume":"29","author":"O Vargas-Sierra","year":"2024","unstructured":"Vargas-Sierra O, Hernandez-Juarez J, Uc-Uc PY, et al. Role of SLC5A8 as a tumor suppressor in cervical cancer. Front Biosci (Landmark Ed). 2024;29(1):16. https:\/\/doi.org\/10.31083\/j.fbl2901016.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"5","key":"1714_CR55","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.cdp.2007.09.002","volume":"31","author":"JY Park","year":"2007","unstructured":"Park JY, Zheng W, Kim D, et al. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev. 2007;31(5):359\u201365. https:\/\/doi.org\/10.1016\/j.cdp.2007.09.002.","journal-title":"Cancer Detect Prev"},{"issue":"5","key":"1714_CR56","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3892\/ijo.2019.4749","volume":"54","author":"J Hernandez-Juarez","year":"2019","unstructured":"Hernandez-Juarez J, Vargas-Sierra O, Herrera LA, et al. Sodium-coupled monocarboxylate transporter is a target of epigenetic repression in cervical cancer. Int J Oncol. 2019;54(5):1613\u201324. https:\/\/doi.org\/10.3892\/ijo.2019.4749.","journal-title":"Int J Oncol"},{"issue":"2","key":"1714_CR57","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cancergencyto.2009.09.004","volume":"196","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Bao YL, Wu Y, et al. Identification and characterization of the human SLC5A8 gene promoter. Cancer Genet Cytogenet. 2010;196(2):124\u201332. https:\/\/doi.org\/10.1016\/j.cancergencyto.2009.09.004.","journal-title":"Cancer Genet Cytogenet"},{"issue":"4","key":"1714_CR58","doi-asserted-by":"publisher","first-page":"971 e971","DOI":"10.1016\/j.urology.2011.04.055","volume":"78","author":"HY Lin","year":"2011","unstructured":"Lin HY, Park HY, Radlein S, et al. Protein expressions and genetic variations of SLC5A8 in prostate cancer risk and aggressiveness. Urology. 2011;78(4):971 e971-979. https:\/\/doi.org\/10.1016\/j.urology.2011.04.055.","journal-title":"Urology"},{"issue":"24","key":"1714_CR59","doi-asserted-by":"publisher","first-page":"9301","DOI":"10.1158\/0008-5472.CAN-09-3073","volume":"69","author":"KL Bennett","year":"2009","unstructured":"Bennett KL, Romigh T, Eng C. Disruption of transforming growth factor-beta signaling by five frequently methylated genes leads to head and neck squamous cell carcinoma pathogenesis. Cancer Res. 2009;69(24):9301\u20135. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3073.","journal-title":"Cancer Res"},{"key":"1714_CR60","doi-asserted-by":"publisher","unstructured":"Liu R Z, Garg M, Yang X H, et al. Docetaxel-induced cell death is regulated by a fatty acid-binding protein 12-Slug-Survivin pathway in prostate cancer cells. Int J Mol Sci 2024;25(17). https:\/\/doi.org\/10.3390\/ijms25179669.","DOI":"10.3390\/ijms25179669"},{"issue":"7","key":"1714_CR61","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/hed.27651","volume":"46","author":"E Benaiges","year":"2024","unstructured":"Benaiges E, Ceperuelo-Mallafr\u00e9 V, Guaita S, et al. Survivin\/BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma. Head Neck. 2024;46(7):1752\u201365. https:\/\/doi.org\/10.1002\/hed.27651.","journal-title":"Head Neck"},{"issue":"2\u20133","key":"1714_CR62","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.mam.2012.07.009","volume":"34","author":"SL Alper","year":"2013","unstructured":"Alper SL, Sharma AK. The SLC26 gene family of anion transporters and channels. Mol Aspects Med. 2013;34(2\u20133):494\u2013515. https:\/\/doi.org\/10.1016\/j.mam.2012.07.009.","journal-title":"Mol Aspects Med"},{"issue":"6","key":"1714_CR63","doi-asserted-by":"publisher","first-page":"C1279","DOI":"10.1152\/ajpcell.00638.2008","volume":"296","author":"H Hayashi","year":"2009","unstructured":"Hayashi H, Suruga K, Yamashita Y. Regulation of intestinal Cl-\/HCO3- exchanger SLC26A3 by intracellular pH. Am J Physiol Cell Physiol. 2009;296(6):C1279-1290. https:\/\/doi.org\/10.1152\/ajpcell.00638.2008.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"9","key":"1714_CR64","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1073\/pnas.90.9.4166","volume":"90","author":"CW Schweinfest","year":"1993","unstructured":"Schweinfest CW, Henderson KW, Suster S, et al. Identification of a colon mucosa gene that is down-regulated in colon adenomas and adenocarcinomas. Proc Natl Acad Sci U S A. 1993;90(9):4166\u201370. https:\/\/doi.org\/10.1073\/pnas.90.9.4166.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1714_CR65","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1053\/j.gastro.2008.07.083","volume":"135","author":"NM Walker","year":"2008","unstructured":"Walker NM, Simpson JE, Yen PF, et al. Down-regulated in adenoma Cl\/HCO3 exchanger couples with Na\/H exchanger 3 for NaCl absorption in murine small intestine. Gastroenterology. 2008;135(5):1645-1653 e1643. https:\/\/doi.org\/10.1053\/j.gastro.2008.07.083.","journal-title":"Gastroenterology"},{"issue":"9","key":"1714_CR66","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1042\/BJ20150751","volume":"473","author":"YD Bhutia","year":"2016","unstructured":"Bhutia YD, Babu E, Ramachandran S, et al. SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. Biochem J. 2016;473(9):1113\u201324. https:\/\/doi.org\/10.1042\/BJ20150751.","journal-title":"Biochem J"},{"issue":"2","key":"1714_CR67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/molehr\/gal009","volume":"12","author":"S Hihnala","year":"2006","unstructured":"Hihnala S, Kujala M, Toppari J, et al. Expression of SLC26A3, CFTR and NHE3 in the human male reproductive tract: role in male subfertility caused by congenital chloride diarrhoea. Mol Hum Reprod. 2006;12(2):107\u201311. https:\/\/doi.org\/10.1093\/molehr\/gal009.","journal-title":"Mol Hum Reprod"},{"issue":"5","key":"1714_CR68","doi-asserted-by":"publisher","first-page":"110691","DOI":"10.1016\/j.ygeno.2023.110691","volume":"115","author":"JY Chen","year":"2023","unstructured":"Chen JY, Huang XY, Lin F, et al. A tumor-associated macrophages related model for predicting biochemical recurrence and tumor immune environment in prostate cancer. Genomics. 2023;115(5):110691. https:\/\/doi.org\/10.1016\/j.ygeno.2023.110691.","journal-title":"Genomics"},{"issue":"8","key":"1714_CR69","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00424-024-02975-4","volume":"476","author":"PL Ljungholm","year":"2024","unstructured":"Ljungholm PL, Ermund A, SoderlundGarsveden MM, et al. The anion exchanger slc26a3 regulates colonic mucus expansion during steady state and in response to prostaglandin E(2), while Cftr regulates de novo mucus release in response to carbamylcholine. Pflugers Arch. 2024;476(8):1209\u201319. https:\/\/doi.org\/10.1007\/s00424-024-02975-4.","journal-title":"Pflugers Arch"},{"issue":"5","key":"1714_CR70","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1210\/en.2012-2074","volume":"154","author":"BT Vo","year":"2013","unstructured":"Vo BT, Morton D Jr, Komaragiri S, et al. TGF-beta effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K\/AKT\/mTOR pathway. Endocrinology. 2013;154(5):1768\u201379. https:\/\/doi.org\/10.1210\/en.2012-2074.","journal-title":"Endocrinology"},{"issue":"1","key":"1714_CR71","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41419-023-06292-z","volume":"15","author":"M Ramos-Brossier","year":"2024","unstructured":"Ramos-Brossier M, Romeo-Guitart D, Lante F, et al. Slc20a1 and Slc20a2 regulate neuronal plasticity and cognition independently of their phosphate transport ability. Cell Death Dis. 2024;15(1):20. https:\/\/doi.org\/10.1038\/s41419-023-06292-z.","journal-title":"Cell Death Dis"},{"key":"1714_CR72","doi-asserted-by":"publisher","first-page":"41233","DOI":"10.1038\/srep41233","volume":"7","author":"AA Bobko","year":"2017","unstructured":"Bobko AA, Eubank TD, Driesschaert B, et al. Interstitial inorganic phosphate as a tumor microenvironment marker for tumor progression. Sci Rep. 2017;7:41233. https:\/\/doi.org\/10.1038\/srep41233.","journal-title":"Sci Rep"},{"issue":"1","key":"1714_CR73","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200802-306OC","volume":"179","author":"H Jin","year":"2009","unstructured":"Jin H, Xu CX, Lim HT, et al. High dietary inorganic phosphate increases lung tumorigenesis and alters Akt signaling. Am J Respir Crit Care Med. 2009;179(1):59\u201368. https:\/\/doi.org\/10.1164\/rccm.200802-306OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1714_CR74","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ceb.2017.02.007","volume":"45","author":"EC Lien","year":"2017","unstructured":"Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Curr Opin Cell Biol. 2017;45:62\u201371. https:\/\/doi.org\/10.1016\/j.ceb.2017.02.007.","journal-title":"Curr Opin Cell Biol"},{"issue":"3","key":"1714_CR75","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3892\/ol.2024.14558","volume":"28","author":"I Matsuoka","year":"2024","unstructured":"Matsuoka I, Kasai T, Onaga C, et al. Co-expression of SLC20A1 and ALDH1A3 is associated with poor prognosis, and SLC20A1 is required for the survival of ALDH1-positive pancreatic cancer stem cells. Oncol Lett. 2024;28(3):426. https:\/\/doi.org\/10.3892\/ol.2024.14558.","journal-title":"Oncol Lett"},{"issue":"4","key":"1714_CR76","doi-asserted-by":"publisher","first-page":"439","DOI":"10.21873\/cdp.10237","volume":"3","author":"T Okamoto","year":"2023","unstructured":"Okamoto T, Onaga C, Matsuoka I, et al. High SLC20A1 expression indicates poor prognosis in prostate cancer. Cancer Diagn Progn. 2023;3(4):439\u201348. https:\/\/doi.org\/10.21873\/cdp.10237.","journal-title":"Cancer Diagn Progn"},{"issue":"1","key":"1714_CR77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.21873\/anticanres.14750","volume":"41","author":"C Onaga","year":"2021","unstructured":"Onaga C, Tamori S, Motomura H, et al. High SLC20A1 expression is associated with poor prognoses in Claudin-low and Basal-like. Breast Cancers. 2021;41(1):43\u201354. https:\/\/doi.org\/10.21873\/anticanres.14750.","journal-title":"Breast Cancers."},{"key":"1714_CR78","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.2147\/ott.S156716","volume":"11","author":"Z Dong","year":"2018","unstructured":"Dong Z, Wang J, Zhan T, et al. Identification of prognostic risk factors for esophageal adenocarcinoma using bioinformatics analysis. Onco Targets Ther. 2018;11:4327\u201337. https:\/\/doi.org\/10.2147\/ott.S156716.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"1714_CR79","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/j.clbc.2016.11.005","volume":"17","author":"K Sato","year":"2017","unstructured":"Sato K, Akimoto K. Expression levels of KMT2C and SLC20A1 identified by information-theoretical analysis are powerful prognostic biomarkers in estrogen receptor-positive breast cancer. Clin Breast Cancer. 2017;17(3):e135\u201342. https:\/\/doi.org\/10.1016\/j.clbc.2016.11.005.","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"1714_CR80","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.18632\/aging.203974","volume":"14","author":"J Ouyang","year":"2022","unstructured":"Ouyang J, Hu Z, Tong J, et al. Construction and evaluation of a nomogram for predicting survival in patients with lung cancer. Aging. 2022;14(6):2775\u201392. https:\/\/doi.org\/10.18632\/aging.203974.","journal-title":"Aging"},{"issue":"43","key":"1714_CR81","doi-asserted-by":"publisher","first-page":"43ra55","DOI":"10.1126\/scitranslmed.3001065","volume":"2","author":"JN Andersen","year":"2010","unstructured":"Andersen JN, Sathyanarayanan S, Di Bacco A, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med. 2010;2(43):43ra55. https:\/\/doi.org\/10.1126\/scitranslmed.3001065.","journal-title":"Sci Transl Med"},{"issue":"9","key":"1714_CR82","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41419-024-07026-5","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Liu Y, Zhao Q, et al. PILRB potentiates the PI3K\/AKT signaling pathway and reprograms cholesterol metabolism to drive gastric tumorigenesis and metastasis. Cell Death Dis. 2024;15(9):642. https:\/\/doi.org\/10.1038\/s41419-024-07026-5.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1714_CR83","doi-asserted-by":"publisher","first-page":"20471","DOI":"10.1038\/s41598-024-71602-0","volume":"14","author":"Y Ma","year":"2024","unstructured":"Ma Y, Zhang Y, Jiang X, et al. KIFC3 promotes the proliferation, migration and invasion of non-small cell lung cancer through the PI3K\/AKT signaling pathway. Sci Rep. 2024;14(1):20471. https:\/\/doi.org\/10.1038\/s41598-024-71602-0.","journal-title":"Sci Rep"},{"issue":"2","key":"1714_CR84","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/ajcn\/nqab342","volume":"115","author":"L Lv","year":"2022","unstructured":"Lv L, Ye D, Chen J, et al. Circulating phosphorus concentration and risk of prostate cancer: a Mendelian randomization study. Am J Clin Nutr. 2022;115(2):534\u201343. https:\/\/doi.org\/10.1093\/ajcn\/nqab342.","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"1714_CR85","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00424-024-02941-0","volume":"476","author":"D Burns","year":"2024","unstructured":"Burns D, Berlinguer-Palmini R, Werner A. XPR1: a regulator of cellular phosphate homeostasis rather than a Pi exporter. Pflugers Arch. 2024;476(5):861\u20139. https:\/\/doi.org\/10.1007\/s00424-024-02941-0.","journal-title":"Pflugers Arch"},{"issue":"5","key":"1714_CR86","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.18632\/aging.205597","volume":"16","author":"X Qian","year":"2024","unstructured":"Qian X, Jin M, Bei Y, et al. SLC20A1 is a prospective prognostic and therapy response predictive biomarker in head and neck squamous cell carcinoma. Aging (Albany NY). 2024;16(5):4423\u201344. https:\/\/doi.org\/10.18632\/aging.205597.","journal-title":"Aging (Albany NY)"},{"key":"1714_CR87","doi-asserted-by":"publisher","unstructured":"Takahashi H, Yoshimatsu G, Faustman DL. The roles of TNFR2 signaling in cancer cells and the tumor microenvironment and the potency of TNFR2 targeted therapy. Cells 2022;11(12). https:\/\/doi.org\/10.3390\/cells11121952.","DOI":"10.3390\/cells11121952"},{"issue":"5","key":"1714_CR88","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/s41375-018-0292-9","volume":"33","author":"H Torrey","year":"2019","unstructured":"Torrey H, Khodadoust M, Tran L, et al. Targeted killing of TNFR2-expressing tumor cells and T(regs) by TNFR2 antagonistic antibodies in advanced Sezary syndrome. Leukemia. 2019;33(5):1206\u201318. https:\/\/doi.org\/10.1038\/s41375-018-0292-9.","journal-title":"Leukemia"},{"issue":"1","key":"1714_CR89","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.yexcr.2014.05.014","volume":"326","author":"IB Kongsfelt","year":"2014","unstructured":"Kongsfelt IB, Byskov K, Pedersen LE, et al. High levels of the type III inorganic phosphate transporter PiT1 (SLC20A1) can confer faster cell adhesion. Exp Cell Res. 2014;326(1):57\u201367. https:\/\/doi.org\/10.1016\/j.yexcr.2014.05.014.","journal-title":"Exp Cell Res"},{"issue":"2","key":"1714_CR90","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.bbcan.2018.05.001","volume":"1870","author":"MA Lacerda-Abreu","year":"2018","unstructured":"Lacerda-Abreu MA, Russo-Abrahao T, Monteiro RQ, et al. Inorganic phosphate transporters in cancer: functions, molecular mechanisms and possible clinical applications. Biochim Biophys Acta Rev Cancer. 2018;1870(2):291\u20138. https:\/\/doi.org\/10.1016\/j.bbcan.2018.05.001.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2\u20133","key":"1714_CR91","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.mam.2012.07.007","volume":"34","author":"IC Forster","year":"2013","unstructured":"Forster IC, Hernando N, Biber J, et al. Phosphate transporters of the SLC20 and SLC34 families. Mol Aspects Med. 2013;34(2\u20133):386\u201395. https:\/\/doi.org\/10.1016\/j.mam.2012.07.007.","journal-title":"Mol Aspects Med"},{"issue":"8","key":"1714_CR92","doi-asserted-by":"publisher","first-page":"E1769","DOI":"10.1073\/pnas.1720739115","volume":"115","author":"S Jenkitkasemwong","year":"2018","unstructured":"Jenkitkasemwong S, Akinyode A, Paulus E, et al. SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice. Proc Natl Acad Sci U S A. 2018;115(8):E1769\u201378. https:\/\/doi.org\/10.1073\/pnas.1720739115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1714_CR93","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12933-024-02224-z","volume":"23","author":"Y Aierken","year":"2024","unstructured":"Aierken Y, He H, Li R, et al. Inhibition of Slc39a14\/Slc39a8 reduce vascular calcification via alleviating iron overload induced ferroptosis in vascular smooth muscle cells. Cardiovasc Diabetol. 2024;23(1):186. https:\/\/doi.org\/10.1186\/s12933-024-02224-z.","journal-title":"Cardiovasc Diabetol"},{"key":"1714_CR94","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/bs.mie.2023.04.019","volume":"687","author":"V Vungutur","year":"2023","unstructured":"Vungutur V, Yu S, McCabe S, et al. A simple and highly reproducible method for the detection of erythrocyte membrane ZIP metal transporters by immunoblotting. Methods Enzymol. 2023;687:87\u2013102. https:\/\/doi.org\/10.1016\/bs.mie.2023.04.019.","journal-title":"Methods Enzymol"},{"key":"1714_CR95","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.freeradbiomed.2024.08.002","volume":"223","author":"B Zhang","year":"2024","unstructured":"Zhang B, Wang E, Zhou S, et al. RELA-mediated upregulation of LINC03047 promotes ferroptosis in silica-induced pulmonary fibrosis via SLC39A14. Free Radic Biol Med. 2024;223:250\u201362. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.08.002.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"1714_CR96","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1186\/s12885-023-11637-0","volume":"23","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wu X, Zhu J, et al. Knockdown of SLC39A14 inhibits glioma progression by promoting erastin-induced ferroptosis SLC39A14 knockdown inhibits glioma progression. BMC Cancer. 2023;23(1):1120. https:\/\/doi.org\/10.1186\/s12885-023-11637-0.","journal-title":"BMC Cancer"},{"key":"1714_CR97","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.2147\/OTT.S103640","volume":"9","author":"XM Xu","year":"2016","unstructured":"Xu XM, Wang CG, Zhu YD, et al. Decreased expression of SLC 39A14 is associated with tumor aggressiveness and biochemical recurrence of human prostate cancer. Onco Targets Ther. 2016;9:4197\u2013205. https:\/\/doi.org\/10.2147\/OTT.S103640.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"1714_CR98","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10534-007-9129-0","volume":"21","author":"AL Albrecht","year":"2008","unstructured":"Albrecht AL, Somji S, Sens MA, et al. Zinc transporter mRNA expression in the RWPE-1 human prostate epithelial cell line. Biometals. 2008;21(4):405\u201316. https:\/\/doi.org\/10.1007\/s10534-007-9129-0.","journal-title":"Biometals"},{"issue":"4","key":"1714_CR99","doi-asserted-by":"publisher","first-page":"e1160","DOI":"10.1002\/mgg3.1160","volume":"8","author":"D Jiang","year":"2020","unstructured":"Jiang D, Jin H, Zuo J, et al. Potential biomarkers screening to predict side effects of dexamethasone in different cancers. Mol Genet Genomic Med. 2020;8(4):e1160. https:\/\/doi.org\/10.1002\/mgg3.1160.","journal-title":"Mol Genet Genomic Med"},{"key":"1714_CR100","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09908-7","author":"K Sobieska","year":"2024","unstructured":"Sobieska K, Buczynska A, Kretowski AJ, et al. Iron homeostasis and insulin sensitivity: unraveling the complex interactions. Rev Endocr Metab Disord. 2024. https:\/\/doi.org\/10.1007\/s11154-024-09908-7.","journal-title":"Rev Endocr Metab Disord"},{"issue":"16","key":"1714_CR101","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.Ccr-16-2245","volume":"23","author":"EA Mostaghel","year":"2017","unstructured":"Mostaghel EA, Cho E, Zhang A, et al. Association of tissue abiraterone levels and SLCO genotype with intraprostatic steroids and pathologic response in men with high-risk localized prostate cancer. Clin Cancer Res. 2017;23(16):4592\u2013601. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-2245.","journal-title":"Clin Cancer Res"},{"issue":"1\u20132","key":"1714_CR102","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/carcin\/bgad075","volume":"45","author":"SH Rajanala","year":"2024","unstructured":"Rajanala SH, Plym A, Vaselkiv JB, et al. SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis. Carcinogenesis. 2024;45(1\u20132):35\u201344. https:\/\/doi.org\/10.1093\/carcin\/bgad075.","journal-title":"Carcinogenesis"},{"issue":"20","key":"1714_CR103","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1158\/0008-5472.Can-11-0532","volume":"71","author":"C Cai","year":"2011","unstructured":"Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71(20):6503\u201313. https:\/\/doi.org\/10.1158\/0008-5472.Can-11-0532.","journal-title":"Cancer Res"},{"issue":"1","key":"1714_CR104","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2217\/pgs-2019-0125","volume":"21","author":"E Johnson","year":"2020","unstructured":"Johnson E, Nussenzveig R, Agarwal N, et al. Germline variants and response to systemic therapy in advanced prostate cancer. Pharmacogenomics. 2020;21(1):75\u201381. https:\/\/doi.org\/10.2217\/pgs-2019-0125.","journal-title":"Pharmacogenomics"},{"key":"1714_CR105","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/2052-8426-2-15","volume":"2","author":"Q Li","year":"2014","unstructured":"Li Q, Shu Y. Role of solute carriers in response to anticancer drugs. Mol Cell Ther. 2014;2:15. https:\/\/doi.org\/10.1186\/2052-8426-2-15.","journal-title":"Mol Cell Ther"},{"issue":"9","key":"1714_CR106","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/pros.24700","volume":"84","author":"J Kim","year":"2024","unstructured":"Kim J, Park S, Kim S, et al. Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells. Prostate. 2024;84(9):814\u201322. https:\/\/doi.org\/10.1002\/pros.24700.","journal-title":"Prostate"},{"key":"1714_CR107","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fgene.2019.00730","volume":"10","author":"EA Pudova","year":"2019","unstructured":"Pudova EA, Lukyanova EN, Nyushko KM, et al. Differentially expressed genes associated with prognosis in locally advanced lymph node-negative prostate cancer. Front Genet. 2019;10:730. https:\/\/doi.org\/10.3389\/fgene.2019.00730.","journal-title":"Front Genet"},{"issue":"21","key":"1714_CR108","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1080\/10408398.2021.2013158","volume":"63","author":"A Gasmi","year":"2023","unstructured":"Gasmi A, Bjorklund G, Noor S, et al. Nutritional and surgical aspects in prostate disorders. Crit Rev Food Sci Nutr. 2023;63(21):5138\u201354. https:\/\/doi.org\/10.1080\/10408398.2021.2013158.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"29","key":"1714_CR109","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1016\/S0021-9258(18)38267-X","volume":"265","author":"WM Pardridge","year":"1990","unstructured":"Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. J Biol Chemistry. 1990;265(29):18035\u201340.","journal-title":"J Biol Chemistry"},{"issue":"4","key":"1714_CR110","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1161\/circresaha.119.316463","volume":"127","author":"K Veys","year":"2020","unstructured":"Veys K, Fan Z, Ghobrial M, et al. Role of the GLUT1 glucose transporter in postnatal CNS angiogenesis and blood-brain barrier integrity. Circ Res. 2020;127(4):466\u201382. https:\/\/doi.org\/10.1161\/circresaha.119.316463.","journal-title":"Circ Res"},{"issue":"4","key":"1714_CR111","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/s0002-9440(10)63924-7","volume":"162","author":"J Chen","year":"2003","unstructured":"Chen J, Zhao S, Nakada K, et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol. 2003;162(4):1283\u201391. https:\/\/doi.org\/10.1016\/s0002-9440(10)63924-7.","journal-title":"Am J Pathol"},{"issue":"10","key":"1714_CR112","doi-asserted-by":"publisher","first-page":"710","DOI":"10.14348\/molcells.2021.0093","volume":"44","author":"HS Kim","year":"2021","unstructured":"Kim HS, Kang YH, Lee J, et al. Biphasic regulation of mitogen-activated protein kinase phosphatase 3 in hypoxic colon cancer cells. Mol Cells. 2021;44(10):710\u201322. https:\/\/doi.org\/10.14348\/molcells.2021.0093.","journal-title":"Mol Cells"},{"key":"1714_CR113","doi-asserted-by":"publisher","first-page":"554078","DOI":"10.3389\/fendo.2021.554078","volume":"12","author":"R Cannarella","year":"2021","unstructured":"Cannarella R, Condorelli RA, Barbagallo F, et al. Endocrinology of the aging prostate: current concepts. Front Endocrinol (Lausanne). 2021;12:554078. https:\/\/doi.org\/10.3389\/fendo.2021.554078.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"16","key":"1714_CR114","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/pros.20662","volume":"67","author":"ND Tararova","year":"2007","unstructured":"Tararova ND, Narizhneva N, Krivokrisenko V, et al. Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate. 2007;67(16):1801\u201315. https:\/\/doi.org\/10.1002\/pros.20662.","journal-title":"Prostate"},{"issue":"3","key":"1714_CR115","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/03915603221111125","volume":"90","author":"S Vovdenko","year":"2023","unstructured":"Vovdenko S, Morozov A, Ali S, et al. Role of monocarboxylate transporters and glucose transporters in prostate cancer. Urologia. 2023;90(3):491\u20138. https:\/\/doi.org\/10.1177\/03915603221111125.","journal-title":"Urologia"},{"key":"1714_CR116","doi-asserted-by":"publisher","unstructured":"Luo Y, Yang Z, Yu Y, et al. HIF1\u03b1 lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in prostate cancer. Int J Biol Macromol. 2022;222(Pt B):2225\u201343. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.10.014.","DOI":"10.1016\/j.ijbiomac.2022.10.014"},{"issue":"3","key":"1714_CR117","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1159\/000485242","volume":"10","author":"JC van der Mijn","year":"2017","unstructured":"van der Mijn JC, Kuiper MJ, Siegert CEH, et al. Lactic acidosis in prostate cancer: consider the Warburg effect. Case Rep Oncol. 2017;10(3):1085\u201391. https:\/\/doi.org\/10.1159\/000485242.","journal-title":"Case Rep Oncol"},{"key":"1714_CR118","doi-asserted-by":"publisher","unstructured":"Wang J X, Choi S Y C, Niu X, et al. Lactic acid and an acidic tumor microenvironment suppress anticancer immunity. Int J Mol Sci 2020, 21(21). https:\/\/doi.org\/10.3390\/ijms21218363.","DOI":"10.3390\/ijms21218363"},{"key":"1714_CR119","doi-asserted-by":"publisher","unstructured":"Choi D, Lee J G, Heo S H, et al. Curcumin and its potential to target the glycolytic behavior of lactate-acclimated prostate carcinoma cells with docetaxel. Nutrients 2024;16(24). https:\/\/doi.org\/10.3390\/nu16244338.","DOI":"10.3390\/nu16244338"},{"issue":"1","key":"1714_CR120","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2217\/fon.09.145","volume":"6","author":"KM Kennedy","year":"2010","unstructured":"Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Futur Oncol (London, England). 2010;6(1):127\u201348. https:\/\/doi.org\/10.2217\/fon.09.145.","journal-title":"Futur Oncol (London, England)"},{"issue":"1","key":"1714_CR121","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ccr.2010.06.007","volume":"18","author":"TSK Eisinger-Mathason","year":"2010","unstructured":"Eisinger-Mathason TSK, Simon MC. HIF-1\u03b1 partners with FoxA2, a neuroendocrine-specific transcription factor, to promote tumorigenesis. Cancer Cell. 2010;18(1):3\u20134. https:\/\/doi.org\/10.1016\/j.ccr.2010.06.007.","journal-title":"Cancer Cell"},{"key":"1714_CR122","doi-asserted-by":"publisher","first-page":"594464","DOI":"10.3389\/fcell.2020.594464","volume":"8","author":"KA Na\u0142\u0119cz","year":"2020","unstructured":"Na\u0142\u0119cz KA. Amino acid transporter SLC6A14 (ATB(0,+)) - a target in combined anti-cancer therapy. Front Cell Dev Biol. 2020;8:594464. https:\/\/doi.org\/10.3389\/fcell.2020.594464.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"1714_CR123","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4103\/aja2022105","volume":"25","author":"B Zhao","year":"2023","unstructured":"Zhao B, Wang J, Chen L, et al. The role of glutamine metabolism in castration-resistant prostate cancer. Asian J Androl. 2023;25(2):192\u20137. https:\/\/doi.org\/10.4103\/aja2022105.","journal-title":"Asian J Androl"},{"issue":"3","key":"1714_CR124","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/sj.pcan.4500879","volume":"9","author":"Y Liu","year":"2006","unstructured":"Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prost Cancer Prostat Dis. 2006;9(3):230\u20134. https:\/\/doi.org\/10.1038\/sj.pcan.4500879.","journal-title":"Prost Cancer Prostat Dis"},{"issue":"9","key":"1714_CR125","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","volume":"125","author":"F Ahmad","year":"2021","unstructured":"Ahmad F, Cherukuri MK, Choyke PL. Metabolic reprogramming in prostate cancer. Br J Cancer. 2021;125(9):1185\u201396. https:\/\/doi.org\/10.1038\/s41416-021-01435-5.","journal-title":"Br J Cancer"},{"issue":"11","key":"1714_CR126","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.biocel.2012.08.013","volume":"44","author":"CV Vaz","year":"2012","unstructured":"Vaz CV, Alves MG, Marques R, et al. Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile. Int J Biochem Cell Biol. 2012;44(11):2077\u201384. https:\/\/doi.org\/10.1016\/j.biocel.2012.08.013.","journal-title":"Int J Biochem Cell Biol"},{"issue":"20","key":"1714_CR127","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1158\/0008-5472.CAN-17-0764","volume":"77","author":"VL Payen","year":"2017","unstructured":"Payen VL, Hsu MY, R\u00e4decke KS, et al. Monocarboxylate transporter MCT1 promotes tumor metastasis independently of its activity as a lactate transporter. Can Res. 2017;77(20):5591\u2013601. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0764.","journal-title":"Can Res"},{"issue":"13","key":"1714_CR128","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/0008-5472.Can-08-0594","volume":"68","author":"SM Dehm","year":"2008","unstructured":"Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68(13):5469\u201377. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-0594.","journal-title":"Cancer Res"},{"key":"1714_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2017.02.010","volume":"135","author":"ML Rives","year":"2017","unstructured":"Rives ML, Javitch JA, Wickenden AD. Potentiating SLC transporter activity: Emerging drug discovery opportunities. Biochem Pharmacol. 2017;135:1\u201311. https:\/\/doi.org\/10.1016\/j.bcp.2017.02.010.","journal-title":"Biochem Pharmacol"},{"issue":"11\u201312","key":"1714_CR130","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00439-019-02081-x","volume":"138","author":"L Schaller","year":"2019","unstructured":"Schaller L, Lauschke VM. The genetic landscape of the human solute carrier (SLC) transporter superfamily. Hum Genet. 2019;138(11\u201312):1359\u201377. https:\/\/doi.org\/10.1007\/s00439-019-02081-x.","journal-title":"Hum Genet"},{"issue":"3","key":"1714_CR131","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00280-007-0480-1","volume":"61","author":"A Evans","year":"2008","unstructured":"Evans A, Bates V, Troy H, et al. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol. 2008;61(3):377\u201393. https:\/\/doi.org\/10.1007\/s00280-007-0480-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1714_CR132","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/cncr.11293","volume":"97","author":"JD Chandler","year":"2003","unstructured":"Chandler JD, Williams ED, Slavin JL, et al. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer. 2003;97(8):2035\u201342. https:\/\/doi.org\/10.1002\/cncr.11293.","journal-title":"Cancer"},{"key":"1714_CR133","doi-asserted-by":"publisher","first-page":"590576","DOI":"10.3389\/fcell.2020.590576","volume":"8","author":"Y Li","year":"2020","unstructured":"Li Y, Sun XX, Qian DZ, et al. Molecular crosstalk between MYC and HIF in cancer. Front Cell Dev Biol. 2020;8:590576. https:\/\/doi.org\/10.3389\/fcell.2020.590576.","journal-title":"Front Cell Dev Biol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01714-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01714-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01714-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:26:25Z","timestamp":1739946385000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01714-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":133,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1714"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01714-w","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}